The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.
Beta-blockers are prescribed as a matter of course to people following a heart attack, but a study found that people who have not experienced cardiac complications after a heart attack gain no improvement in outcomes by taking beta-blockers long-term.
Sweden: A recent study showed no benefit of Bivalirudin versus heparin in patients with STEMI undergoing primary percutaneous coronary intervention (PCI) with radial access and currently recommended.